Clinical Trials Browser

Phase 1/2 × Interventional × Tumor-Agnostic × Clear all

NCT07193511 2026-04-16

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT02908906 2026-04-13

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

Neoplasms

NCT04317105 2026-04-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT04799054 2026-04-13

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

Neoplasm Metastasis

NCT04802759 2026-04-13

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT05120596 2026-04-13

First in Human Study of T3P-Y058-739 (T3P)

Phase 1/2 Recruiting

Neoplasms

NCT06941272 2026-04-13

MK-9999-01C

Phase 1/2 Recruiting

Neoplasms

NCT07335497 2026-04-13

ASCEND

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT05975073 2026-04-07

A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT01968109 2026-04-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase 1/2 Completed

1,482 enrolled 56 charts

Neoplasms by Site

NCT06238687 2026-04-06

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT07510828 2026-04-06

PRISM-NK

Phase 1/2 Recruiting

Neoplasms

NCT07276373 2026-04-03

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

Neoplasms

NCT04713046 2026-04-02

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Completed

Neoplasms

NCT07213817 2026-04-01

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07213830 2026-03-31

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07498725 2026-03-27

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

Phase 1/2 Not yet recruiting

Neoplasms

NCT05046171 2026-03-24

Decreasing Polypharmacy in Older Adults With Curable Cancers Trial

Phase 1/2 Completed

Neoplasms

NCT04333706 2026-03-10

EMPOWER

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT04723810 2026-03-09

TumorGlow Intraoperative Molecular Imaging (IMI)

Phase 1/2 Recruiting

Neoplasms

NCT05004116 2026-03-04

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07354100 2026-03-04

(BLOOM)

Phase 1/2 Not yet recruiting

Neoplasms

NCT06014658 2026-03-02

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

Phase 1/2 Recruiting

Neoplasms

NCT06056791 2026-02-27

CaRe

Phase 1/2 Completed

Neoplasms

NCT06818643 2026-02-19

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Phase 1/2 Recruiting

Neoplasms

NCT06211933 2026-02-12

PULS

Phase 1/2 Suspended

Neoplasms

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase 1/2 Active not recruiting

Neoplasms

NCT06634849 2026-02-10

An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).

Phase 1/2 Recruiting

Neoplasms

NCT05039632 2026-02-06

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT03260023 2026-02-05

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Phase 1/2 Active not recruiting

143 enrolled 24 charts

Neoplasms

NCT06077877 2026-02-02

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT04260529 2026-01-29

CICILIA

Phase 1/2 Completed

60 enrolled 18 charts

Neoplasms

NCT03872778 2026-01-28

NeoRay

Phase 1/2 Completed

Neoplasms

NCT04145622 2026-01-28

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Phase 1/2 Recruiting

Neoplasms

NCT07112222 2026-01-26

A Study of LM-350 in Subjects With Advanced Solid Tumours

Phase 1/2 Recruiting

Neoplasms

NCT07073534 2026-01-22

Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT03096093 2026-01-20

Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

Phase 1/2 Active not recruiting

Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT05741242 2026-01-15

A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Phase 1/2 Enrolling by invitation

Neoplasms

NCT05276284 2026-01-14

TEMPLE

Phase 1/2 Completed

Neoplasm Metastasis

NCT05450562 2026-01-14

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Phase 1/2 Terminated

Neoplasms

NCT05875168 2026-01-12

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT05858229 2025-12-31

Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.

Phase 1/2 Active not recruiting

Carcinoma, Squamous Cell

NCT06320405 2025-12-29

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07197827 2025-12-24

A Study of YL242 in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasms

NCT05566574 2025-12-17

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT05731271 2025-12-17

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT04009681 2025-12-15

HAMMER

Phase 1/2 Terminated

Neoplasm Metastasis, Neoplasms